Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds potential way to improve cancer immunotherapy

05.09.2003


Drugs that contain antibodies are a standard part of therapy for many cancers, but these antibodies do not always work. A finding by researchers with the Holden Comprehensive Cancer Center at the University of Iowa may help make the antibodies more effective by boosting the power of white blood cells, which play a role in fighting cancer.



One way that antibodies ideally function is to stick to cancer cells and signal various types of white blood cells to kill the cancer cells. The UI Holden Center team and colleagues used mouse cell lines that mimic human conditions to learn how different types of white blood cells work with antibodies and contribute to killing cancer cells. The team used different classes of an immune stimulant known as CpG ODN (CpG oligodeoxynucleotide) to encourage different types of white blood cells, either separately or together, to work with antibodies to kill cancer.

The new information could help doctors make antibodies more effective by providing a way to gear up specific types of white blood cells -- natural killer cells and granulocytes -- at the same time that patients receive a dose of anti-cancer antibodies, said George Weiner, M.D., UI professor of internal medicine, director of the Holden Comprehensive Cancer Center and principal investigator for the study. The findings appear in the Sept. 1 issue of the journal Cancer Research.


"Previous research suggested that different white blood cells can kill cancer cells," Weiner said. "We found that by selecting other agents as stimulants, we can specially direct one type or another of white blood cells to do the killing. It’s an extra measure of control for the white blood cells that you specifically want to activate to destroy the cancer cells."

Weiner said the finding potentially could lead to improved therapies for patients. The UI currently is evaluating this approach in clinical trials.

Monoclonal antibodies currently used in cancer therapies include rituximab (Rituxan) for certain types of non-Hodgkin’s lymphoma and trastuzumab (Herceptin) for breast cancer.

People do not normally have these antibodies in their system. The cancer-fighting versions are based on natural antibodies and designed to react with cancer cells, Weiner said. With cancers, the immune system fails to recognize tumors as invaders -- that is where drugs can step in and make a difference.

"Using antibodies is a way of taking the immune system and redirecting it toward killing the cancer," Weiner said.

Non-Hodgkin’s lymphoma is cancer of the lymphatic system, which normally fights infection. The lymphatic system includes lymph nodes and parts of the body that include lymphatic tissues: the spleen, thymus gland, bone marrow, adenoids and tonsils.


###
Contributors to the study included investigators at the University Medical Center Utrecht in the Netherlands.

Funding for the study included a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). For information on that grant, visit http://www.uiowa.edu/~ournews/2002/september/0918SPORE.html. The study also included support from Coley Pharmaceutical Group. Weiner serves as a consultant for Coley.

The Holden Comprehensive Cancer Center is Iowa’s only National Cancer Institute (NCI)-designated comprehensive cancer center. NCI-designated comprehensive cancer centers are recognized as the leaders in developing new approaches to cancer prevention and cancer care, conducting leading edge research and educating the public about cancer.

University of Iowa Health Care describes the partnership between the UI Roy J. and Lucille A. Carver College of Medicine and UI Hospitals and Clinics and the patient care, medical education and research programs and services they provide. Visit UI Health Care online at www.uihealthcare.com.

Becky Soglin | EurekAlert!
Further information:
http://www.uiowa.edu/~ournews/2002/september/0918SPORE.html
http://www.uihealthcare.com

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>